Leo Pharma awaiting final decision on antibody after phase II defeat
The Danish medical dermatology company paid DKK 270m for a candidate that did not meet mid-stage testing goals in atopic eczema – but it might still have potential in another disease.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
A monoclonal antibody, which Leo Pharma calls Anti IgE+B cell, has failed in phase IIa testing in the atopic dermatitis indication, meeting neither primary nor secondary endpoints.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma enters partnership with Irish CRO
For subscribers
.jpg&w=384&q=75)
